ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Melanoma

Developments in the Screening and Prognostication of Melanoma

In this peer-to-peer discussion, Ahmad A. Tarhini, MD, PhD, of the UPMC Hillman Cancer Center, and Sancy Leachman, MD, PhD, of the OHSU Knight Cancer Institute, review the current strategies for managing patients with melanoma, including screening and prognosis for high-risk patients and how to choose the best therapies to avoid toxicities and treatment resistance.

Melanoma

The FDA has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease.

Patients with advanced melanoma treated with nivolumab had higher and more durable responses compared with investigator’s choice of chemotherapy, but these increases did not result in improved survival outcomes.

Treatment of advanced melanoma with the checkpoint inhibitor nivolumab beyond RECIST-defined progression resulted in clinical benefit for selected patients, according to pooled, retrospective data from two phase III trials.

In this interview we discuss the effect of the gut microbiome on responses and survival outcomes in metastatic melanoma patients treated with anti–PD-1 immunotherapies.

Treatment with single-agent bevacizumab resulted in an improved disease-free interval in patients with resected melanoma, but no increase in overall survival compared with observation.

Patients with node-positive intermediate-thickness melanoma had an increased rate of regional disease control when undergoing completion lymph-node dissection for sentinel node metastases, however, there was no increase in melanoma-specific survival.

This peer-to-peer discussion reviews the current strategies for managing patients with melanoma, including screening and prognosis for high-risk patients and how to choose the best therapies to avoid toxicities and treatment resistance.

Pages

Subscribe to Melanoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.